Two-Year Real-World Results for Aflibercept Using the Treat-and-Extend Regimen in Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy

IntroductionTo evaluate the real-world efficacy of aflibercept using the treat-and-extend (TnE) regimen in treating neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV), and to analyze biomarkers using optical coherence tomography (OCT) to predict treatment outcomes.MethodsPatients diagnosed with nAMD or PCV who received an intravitreal injection of aflibercept following the TnE regimen for >= 2 years were retrospectively reviewed. Data on best-corrected visual acuity (BCVA), number of injections, treatment interval, and OCT biomarkers, including central macular thickness, presence of subretinal fluid (SRF), and serous pigmented epithelial detachment, were collected at baseline and at 3, 6, 12, 18, and 24 months after the first injection.ResultsA total of 43 patients were enrolled in this study, 24 of whom were diagnosed with nAMD and 19 with PCV. The BCVA in logMAR (mean +/- standard deviation) improved from 0.75 +/- 0.41 (baseline) to 0.60 +/- 0.41 (P = 0.002) at 3 months after treatment initiation, and further improved to 0.66 +/- 0.46 at 24 months (P = 0.137). The number of injections (mean +/- standard deviation) within the 2-year treatment course was 10.95 +/- 3.65. At month 24 of the TnE regimen, the treatment interval was extended to >= 16 weeks in 60.5% of all cases and to 78.9% of the PCV cases. After three loading injections, persistent subretinal fluid and intraretinal fluid were predictive of more frequent injections (P = 0.026) and poorer visual outcomes (P = 0.050), respectively.ConclusionAflibercept combined with a TnE regimen was effective in treating nAMD and PCV in a real-world setting. The treatment interval could be extended to >= 16 weeks in 60.5% of the cases after a 2-year treatment regimen. OCT can be used to predict the treatment course and visual outcomes.

Automated summary

This study evaluated the efficacy of aflibercept combined with a treat-and-extend (TnE) regimen in treating neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) in a real-world setting. The treatment interval could be extended to >= 16 weeks after a 2-year treatment regimen. Optical coherence tomography (OCT) can be used to predict the treatment course and visual outcomes.